OncologyPRO

What's new on OncologyPRO

Haven't had much time lately? Here's what you may have missed in the last few weeks.

LATEST PUBLISHED CONTENT ...

ESMO Congress

European Lung Cancer Congress 2023

29 Mar 2023 Copenhagen

ESMO-Guidelines-Real -World-Cases-Webinar-Series-General-1000x1000px

Aired live on 29 March 2023

ESMO Guidelines: Real World Cases - Webinar Series: Oesophageal Cancer

29 Mar 2023

ESMO Course

ESMO - The Christie Preceptorship on Lung Cancer 2023: Manchester

1 Mar 2023 Manchester

28 Mar 2023

Breast Cancer

ESMO E-Learning: Present and Emerging Treatment Options in HER2-positive Metastatic Breast Cancer

Rupert Bartsch , Christoph C. Zielinski

Virtual Plenary: 27-28 March 2023

Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: The placebo-controlled randomised phase III RUBY trial

27 Mar 2023

Latest in our Congress Watch

31 Mar 2023

Small Cell Lung Cancer

Liposomal Irinotecan Fails To Extend Advanced SCLC Survival

From ELCC 2023:
Liposomal irinotecan does not offer significantly better overall survival than topotecan for patients with small-cell lung cancer that has progressed during or after first-line platinum-based chemotherapy

30 Mar 2023

Non-Small Cell Lung Cancer; Personalised/Precision Medicine

Osimertinib Updates May Help Guide Advanced EGFR-Mutated NSCLC Decisions

From ELCC 2023:
APPLE and NORTHSTAR updates add to understanding of osimertinib use among patients with advanced EGFR-mutated non-small-cell lung cancer

ESMO E-Learning

15 Aug 2020

Our E-Learning webcasts are produced by leading experts in oncology and include a CME test. ESMO Members can access numerous Modules covering all areas of oncology.

Explore the library

ESMO Guidelines

30 Aug 2019

Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.

Discover more

Courses slides & webcasts

1 Aug 2022

Organised by topic, all slides and webcasts are available to ESMO Members.
Check the latest courses published on NSCLC, IO, Breast, Gastric Cancers and precision medicine (KRAS, EGFR, NTRK).

Access courses by topic

Tumour Sites

Explore all ESMO scientific resources and find up to date educational content in your field of interest

Breast Cancer

Carcinoma of Unknown Primary Site

Central Nervous System Malignancies

Endocrine Cancers

Gastrointestinal Cancers

Genitourinary Cancers

Gynaecological Malignancies

Haematological Malignancies

Head and Neck Cancers

Lung and other Thoracic Tumours

Melanoma and other Skin Tumours

Sarcomas

Scientific Videos

All videos on the ESMO Channel: Subscribe now!

Latest in our Congress Watch

31 Mar 2023

Liposomal Irinotecan Fails To Extend Advanced SCLC Survival

From ELCC 2023:
Liposomal irinotecan does not offer significantly better overall survival than topotecan for patients with small-cell lung cancer that has progressed during or after first-line platinum-based chemotherapy

30 Mar 2023

Osimertinib Updates May Help Guide Advanced EGFR-Mutated NSCLC Decisions

From ELCC 2023:
APPLE and NORTHSTAR updates add to understanding of osimertinib use among patients with advanced EGFR-mutated non-small-cell lung cancer

22 Feb 2023

Pembrolizumab May Benefit Patients With Papillary High-Risk NMIBC Unresponsive To BCG

From 2023 ASCO GU Cancers Symposium:
The KEYNOTE-057 trial has shown promising efficacy and safety of pembrolizumab monotherapy for BCG-unresponsive, papillary high-risk non-muscle-invasive bladder cancer

21 Feb 2023

Sacituzumab Govitecan Has ‘Encouraging’ Activity In Platinum-Ineligible, ICI-Treated Metastatic UC

From 2023 ASCO GU Cancers Symposium:
Patients with platinum-ineligible metastatic urothelial cancer that has progressed on immune checkpoint therapy could benefit from treatment with the antibody–drug conjugate sacituzumab govitecan

20 Feb 2023

Novel Agent BXCL701 Plus Pembrolizumab Promising For Small-Cell Neuroendocrine Prostate Cancer

From 2023 ASCO GU Cancers Symposium:
Phase IIa data point to the potential of combining the first-in-class innate immune activator BXCL701 with pembrolizumab in men with refractory small-cell neuroendocrine cancer of the prostate

19 Feb 2023

TRITON3: PFS Boost With Rucaparib For BRCA-Positive Metastatic CRPC

From 2023 ASCO GU Cancers Symposium:
The use of rucaparib alongside a second-generation androgen receptor pathway inhibitor improves the outcome of patients with metastatic castration-resistant prostate cancer

17 Feb 2023

TALAPRO-2 First-Line Regimen Supported For Metastatic CRPC All-Comers

From 2023 ASCO GU Cancers Symposium:
Talazoparib plus enzalutamide has significantly extended radiographical progression-free survival for men with treatment-naïve metastatic castration-resistant prostate cancer

25 Jan 2023

Third-Line Trifluridine–Tipiracil Plus Bevacizumab ‘Represents New Standard Of Care’ For mCRC

From 2023 ASCO GI Cancers Symposium:
The SUNLIGHT trial shows a significant improvement in the overall survival of patients with refractory metastatic colorectal cancer with the addition of bevacizumab to trifluridine and tipiracil

More News

Join ESMO today for full access to all OncologyPRO Content

Some of the content presented is exclusively for ESMO members - Join today to access all of ESMO’s educational and scientific resources on OncologyPRO.

Become a member